The Division of Pulmonary & Critical Care Medicine at Thomas Jefferson University Hospital is one of the US sites participating in a Research Trial for patients with Scleroderma (SSc) and pulmonary arterial hypertension (PAH). 

The primary purpose of this study is to evaluate the safety and tolerability of rituximab for the treatment of SSc-PAH, while evaluating the drug's effect on PAH.  The use of rituximab for the treatment of SSc-PAH in this research study is investigational. 

For more information please call one of the following:

Elizabeth Grace, Study Coordinator